MarketPeel
Insider Trading Intelligence
JP

James T. Parsons

DMAC
DIRECTOR · DIAMEDICA THERAPEUTICS INC. · CIK 0001759855
FILING MIX · LIFETIME94%/6%
BUYS
17
SELLS
1
TOTAL VALUE
$427.7K
COMPANIES
2
ACTIVE SINCE
Jun 2020
HOLDINGS NOW
81,189
AVG SELL PX
TRADE KIND
SHOWING 18 / 18
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizons · 3 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by James T. Parsons, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+0.00%-4.95%-2.20%-2.75%-2.75%
14d1+0.00%-5.94%-2.88%-3.06%-3.06%
30d1+0.00%-7.92%+0.46%-8.38%-8.38%
60d1+0.00%-10.89%+9.31%-20.20%-20.20%
90d1+0.00%-16.83%+9.30%-26.13%-26.13%
180d1(1 pending)
1y1(1 pending)
2y1(1 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
DMAC · 51,189 shares · as of Jun 1, 2026
024,48748,97573,46297,949202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 17 buys / 1 sellsCOVERAGE · 25 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
DMAC
DIAMEDICA THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
51,18951,189Jun 1, 2026Jun 3, 2026View →
ONCY
ONCOLYTICS BIOTECH INC
PURCHASEGRANT
Stock grant
30,00030,000Jun 1, 2026Jun 3, 2026View →
ONCY
ONCOLYTICS BIOTECH INC
PURCHASE
10,000$1.03$10.3K41,849Mar 11, 2026Mar 13, 2026View →
DMAC
DIAMEDICA THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
10,095$8.42$85.0K97,949Jan 2, 2026Jan 6, 2026View →
DMAC
DIAMEDICA THERAPEUTICS INC.
SALE
12,0000Nov 21, 2025Nov 25, 2025View →
DMAC
DIAMEDICA THERAPEUTICS INC.
PURCHASE
12,000$2.20$26.4K87,854Nov 21, 2025Nov 25, 2025View →
DMAC
DIAMEDICA THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
40,73940,739Jun 1, 2025Jun 3, 2025View →
DMAC
DIAMEDICA THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
4,2874,287Jan 2, 2025Jan 3, 2025View →
DMAC
DIAMEDICA THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
15,917$5.34$85.0K75,854Jan 2, 2025Jan 3, 2025View →
DMAC
DIAMEDICA THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
28,47228,472Jun 1, 2024Jun 3, 2024View →
DMAC
DIAMEDICA THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
21,428$2.80$60.0K59,937Jan 2, 2024Jan 2, 2024View →
DMAC
DIAMEDICA THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
16,96816,968Jun 1, 2023Jun 2, 2023View →
DMAC
DIAMEDICA THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
13,22213,222Jun 1, 2022Jun 2, 2022View →
DMAC
DIAMEDICA THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
16,773$3.58$60.0K38,509Jan 3, 2022Jan 3, 2022View →
DMAC
DIAMEDICA THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
9,3939,393Jul 15, 2021Jul 16, 2021View →
DMAC
DIAMEDICA THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
7,745$8.23$63.7K21,947Jan 1, 2021Jan 4, 2021View →
DMAC
DIAMEDICA THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
8,102$4.59$37.2K14,202Jun 1, 2020Jun 2, 2020View →
DMAC
DIAMEDICA THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
13,30613,306Jun 1, 2020Jun 2, 2020View →
Other insiders · DMAC
Loading peer insiders…
About this filer
CIK 0001759855
ROLE
Director
PRIMARY
DMAC
COMPANIES
2
ACTIVE SINCE
Jun 2020
MARKETPEEL · /INSIDER/0001759855DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback